Logo

Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders

Share this

Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders

Shots:

  • Takeda and Frazier enter into collaboration to launch Phathom Pharmaceuticals to develop & commercialize therapies for gastrointestinal diseases and disorders
  • Phathom to get rights to develop & exclusively commercialize Takeda’s Vonoprazan in the US- EU & Canada plus $90M funds & $50M as debt facility from Frazier & Silicon Valley Bank respectively. Takeda to get upfront as cash & equity- milestones- royalties on sales and will retain its right for Asia
  • Takeda’s vonoprazan is an orally active potassium-competitive acid blocker (P-CAB)- blocking the potassium binding site of ATPase indicated for acid-related disorders like GERD- co-promoted by Takeda & Otsuka under 2015 deal

Ref: BusinessWire | Image: Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions